Clinical trials: Symptomatic Dermographism
Chronic Inducible Urticaria
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
This was a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines
- Trial name
- PEARL-PROVOKE (NCT05024058)
- Testing
- Ligelizumab
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Hypersensitivity, Immediate, Autoinflammatory Syndromes
Pathogenesis of Physical Induced Urticarial Syndromes
Background: Urticaria is a common itchy skin disorder that may occur spontaneously or on exposure to a physical trigger (called physical urticaria).
- Conditions
- Hypersensitivity, Immediate, Autoinflammatory Syndromes, Physical Urticaria, Familial Cold Autoinflammatory Syndrome
- Trial name
- NCT00887939
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)